PMID- 18720932
OWN - NLM
STAT- MEDLINE
DCOM- 20080925
LR  - 20160923
IS  - 1784-3227 (Print)
IS  - 1784-3227 (Linking)
VI  - 71
IP  - 2
DP  - 2008 Apr-Jun
TI  - EGFR-immunohistochemistry in colorectal cancer and non-small cell lung cancer: 
      comparison of 3 commercially available EGFR-antibodies.
PG  - 213-8
AB  - BACKGROUND: Epidermal Growth Factor Receptor (EGFR)-targeted therapies are 
      currently used for the treatment of metastasized colorectal cancer (CRC) and non 
      small cell lung cancer (NSCLC). Patient selection for this treatment is based on 
      immunohistochemical (IHC) testing for EGFR. The rising amount of commercially 
      available EGFR-antibodies makes standardisation of EGFR-IHC necessary. The goal 
      of this study was to analyse possible discrepancies between 3 antibodies against 
      EGFR. PATIENTS AND METHODS: 36 formalin-fixed samples of CRC (n = 26) and NSCLC 
      (n = 10) were stained with 3 antibody-clones: 2-18C9 (Dako); 31G7 (VentanaTM) and 
      111.6 (Labvision Neomarkers). Interpretation of stains includes assessment of % 
      positive cells, evaluation of cut off values and staining intensity. RESULTS: 
      With a 1% cut-off, the 2-18C9 clone stained 86% of the cases positive, the 
      31G7-clone 77% and the 111.6-clone 52%. With a 10% cut-off, percentages declined 
      to 77%, 61% and 30% respectively. The 2-18C9-clone showed the highest staining 
      intensity. The 2-18C9 clone and the 31G7-clone showed a concordance rate of 90%. 
      CONCLUSIONS: IHC staining with 3 different antibody clones directed against EGFR 
      shows indeed differences in staining results: the percentage of positive cells 
      and staining intensity are variable. A correct cut-off value for a positive 
      result is important and can be different depending upon the antibody. Appropriate 
      validation of an antibody is essential before it can be used for selection of 
      patients.
FAU - Buffet, W
AU  - Buffet W
AD  - Department of Pathology, University Hospital Gasthuisberg, Leuven. 
      Wendi.Buffet@uz.kuleuven.ac.be
FAU - Geboes, K P
AU  - Geboes KP
FAU - Dehertogh, G
AU  - Dehertogh G
FAU - Geboes, K
AU  - Geboes K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Belgium
TA  - Acta Gastroenterol Belg
JT  - Acta gastro-enterologica Belgica
JID - 0414075
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Biomarkers, Tumor)
RN  - 62229-50-9 (Epidermal Growth Factor)
SB  - IM
MH  - Antibodies, Neoplasm/*analysis
MH  - Biomarkers, Tumor/immunology/metabolism
MH  - Biopsy
MH  - Carcinoma, Non-Small-Cell Lung/immunology/*metabolism/pathology
MH  - Colorectal Neoplasms/immunology/*metabolism/pathology
MH  - Epidermal Growth Factor/immunology/*metabolism
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - Lung Neoplasms/immunology/*metabolism/pathology
EDAT- 2008/08/30 09:00
MHDA- 2008/09/26 09:00
CRDT- 2008/08/30 09:00
PHST- 2008/08/30 09:00 [pubmed]
PHST- 2008/09/26 09:00 [medline]
PHST- 2008/08/30 09:00 [entrez]
PST - ppublish
SO  - Acta Gastroenterol Belg. 2008 Apr-Jun;71(2):213-8.